Table 1. Distribution of Psychotropic Medication.
| Medication | Baseline | Follow-up | ||||
|---|---|---|---|---|---|---|
| Patients With MDD Without Relapse (n = 23) | Patients With MDD With Relapse (n = 37) | P Valuea | Patients With MDD Without Relapse (n = 23) | Patients With MDD With Relapse (n = 37) | P Valuea | |
| Antidepressants, No. (%) | ||||||
| SSRI | 6 (26) | 8 (22) | .69 | 5 (22) | 5 (14) | .41 |
| SSNRI | 11 (48) | 19 (51) | .79 | 7 (30) | 19 (51) | .11 |
| NaSSA | 4 (17) | 3 (8) | .28 | 2 (9) | 2 (5) | .62 |
| NDRI | 0 | 2 (5) | .26 | 0 | 2 (5) | .26 |
| Tricyclic antidepressant | 0 | 1 (3) | .43 | 0 | 2 (5) | .26 |
| MAO inhibitor | 0 | 0 | NA | 0 | 0 | NA |
| Antipsychotics, No. (%) | 3 (13) | 10 (27) | .20 | 2 (9) | 8 (22) | .19 |
| Mood stabilizers, No. (%) | 0 | 2 (5) | .26 | 1 (4) | 4 (11) | .38 |
| Other, No. (%) | 6 (26) | 7 (19) | .51 | 0 | 2 (5) | .26 |
| None, No. (%) | 1 (4) | 3 (8) | .57 | 11 (48) | 10 (27) | .10 |
Abbreviations: MAO, monoamine oxidase; MDD, major depressive disorder; NA, not applicable; NaSSA, noradrenergic and specific serotonergic antidepressant; NDRI, norepinephrine dopamine reuptake inhibitor; SSNRI, selective serotonin noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
a
Determined by use of the χ2 test.